glycyrrhizic acid and Bone Loss, Perimenopausal
glycyrrhizic acid has been researched along with Bone Loss, Perimenopausal in 2 studies
Research
Studies (2)
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 1 (50.00) | 24.3611 |
2020's | 1 (50.00) | 2.80 |
Authors
Authors | Studies |
---|---|
Bao, YZ; Lv, XL; Tang, Y; Wang, JR | 1 |
Chen, X; Guo, S; Li, S; Liu, T; Ouyang, Z; Peng, D; Wu, Q; Yin, Z; Zhang, Q; Zhu, W | 1 |
Other Studies
2 other study(ies) available for glycyrrhizic acid and Bone Loss, Perimenopausal
Article | Year |
---|---|
Glycyrrhizin improves bone metabolism in ovariectomized mice via inactivating NF-κB signaling.
Topics: Animals; Bone Density Conservation Agents; Bone Resorption; Disease Models, Animal; Female; Glycyrrhizic Acid; Humans; Mice; Mice, Inbred C57BL; Monocytes; NF-kappa B; Osteoclasts; Osteogenesis; Osteoporosis, Postmenopausal; Ovariectomy; RAW 264.7 Cells; Signal Transduction | 2021 |
Glycyrrhizic acid suppresses osteoclast differentiation and postmenopausal osteoporosis by modulating the NF-κB, ERK, and JNK signaling pathways.
Topics: Animals; Cell Differentiation; Extracellular Signal-Regulated MAP Kinases; Gene Expression Regulation; Glycyrrhizic Acid; Humans; JNK Mitogen-Activated Protein Kinases; MAP Kinase Signaling System; Mice; NF-kappa B; Osteoclasts; Osteogenesis; Osteoporosis, Postmenopausal; RANK Ligand; RAW 264.7 Cells | 2019 |